SCHEMBL4723595

SCHEMBL4723595

COc1ccc(Cl)cc1-c1nc(CC(=O)O)co1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.47
ALDH1A1 P00352 7/20 0.47
HPGD P15428 6/20 0.47
DRD2 P14416 2/20 0.46
DRD4 P21917 2/20 0.46
DRD3 P35462 2/20 0.46
HSD17B10 Q99714 2/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.43
USP2 O75604 1/20 0.43
PRNP P04156 1/20 0.43
PPARG P37231 1/20 0.43
MAPK10 P53779 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14098684 0.86 MAPT (0.43) ALDH1A1HPGDDRD2DRD4DRD3
SCHEMBL5116066 0.82 CA2 (0.44) HPGDDRD2DRD4DRD3HSD17B10
SCHEMBL4720371 0.80 PTGER1 (0.50) PTGDR2CTSA
SCHEMBL4278957 0.79 ALDH1A1 (0.60) ALDH1A1HPGDHSD17B10SMN1; SMN2KDM4E
SCHEMBL4719856 0.78 PTGER1 (0.52) PTGDR2
SCHEMBL4723528 0.78 PTGER1 (0.55)
SCHEMBL10029578 0.77 GAA (0.48) ALDH1A1HPGDKMT2AKDM4EPPARG
SCHEMBL10029592 0.73 AGPAT2 (0.42) ALDH1A1ALOX15SMN1; SMN2KDM4ETDP1
SCHEMBL627996 0.73 S1PR1 (0.50) ALDH1A1HPGDKDM4EPPARGGAA
SCHEMBL28787698 0.73 FFAR1 (0.60) SMN1; SMN2L3MBTL1RAB9AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
EP-1874776-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-01-09 EP disclosed
WO-2006114274-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders PTGER1, PTGER2, PTGER4 PTGDR2 6/4885ALDH1A1 647/4885HPGD 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.